Ashling Wahner


Nadofaragene firadenovec, PD-1 inhibitors show synergistic activity in bladder cancer

May 18, 2022

“These findings are hypothesis-generating and suggest a possible therapeutically synergistic role for immune checkpoint blockade in [patients with] BCG-unresponsive NMIBC who may have partial or short-term response to nadofaragene treatment,” said lead study author Anirban P. Mitra, MD, PhD.